Clinical Trial Search

Primary: Biphasic Ethanol Effects Scale (BAES) — 3.767; 3.935; 3.813; 3.194 score on a scale

Primary: Nausea 100 mm Visual Analogue Scale (VAS) — 23; 19; 42 units on a scale

Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants

Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03

Primary: Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax) — 0.0604; 0.202 g/L

Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Across Sessions…

Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants

Primary: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal — 180.5; 112.5; 109.1 mg — p=0.64

Primary: Number of Intervention — 1.9; 7.5 Number of intervention — p=0.05

Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants

Primary: Breath Alcohol — 0.001; 0.075; 0.001; 0.071 gr/dL — p=0.28

Primary: Relapse Rates — 13; 15; 14; 18 Participants

Primary: Treatment Adherence — 15 Participants

Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period — 8.94; 10.37; 9.83; 11.03 units on a…

Primary: Number of Drinks Felt Consumed at Baseline — 0; 0; 0; 0 drinks felt consumed

Primary: Rate (%) of 30-day Hospital Re-admission — 3; 2; 7 Participants

Primary: Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B — 1; 1; 1.009; 0.901 normalized score on a scale

Primary: Craving to Drink — 36.5; 42.9 units on a scale — p=.003

Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale

Primary: Change in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli — 0.267390; 0.040281; 0.058670; -0.069048 BOLD response

Primary: Prefrontal GABA+ Concentrations — 3.90; 3.93; 3.73 mmol/kg

Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine

Primary: Average Standard Drinking Units Per Day — 4.50; 4.48 standard drinking units per day — p=.98

Primary: Time to Nausea Reduction by 50% by Visual Analog Scale. — 4.3; 3.5 Minutes

Primary: Abnormal Labs and Adverse Events — 9; 8; 0; 0 Participants

Primary: Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups — 14.1; 124.4 mg of benzodiazepine per 8 hours

Primary: AOCGIR (Area Over the Curve for Glucose Infusion Rate) — 1996; 1981 mg*minute/dl

Primary: Baseline-to-Exit Change in Drinks Per Drinking Day (TLFB) — -1.98; -2.82; -1.22 Standard Drinks per Drinking Day

Primary: Area Under the Curve of Alfentanil Concentration vs. Time Extrapolated to Infinity — 58; 57; 55; 73 (hr*ng/ml/mg) — p=<.05

Primary: Mean Biphasic Alcohol Effects Scale (BAES) Scores — 27.5; 32.4; 23.0; 21.1 score on a scale